Advertisement

Breast Cancer Research and Treatment

, Volume 125, Issue 3, pp 671–685 | Cite as

COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients

  • Johanna G. H. van Nes
  • Esther M. de Kruijf
  • Dana Faratian
  • Cornelis J. H. van de Velde
  • Hein Putter
  • Claire Falconer
  • Vincent T. H. B. M. Smit
  • Charlene Kay
  • Marc J. van de Vijver
  • Peter J. K. Kuppen
  • John M. S. Bartlett
Preclinical Study

Abstract

In breast cancer, the prognostic impact of COX2 expression varies widely between studies. We examined the prognostic value of COX2 expression in a large cohort of breast cancer patients treated with primary surgery between 1985 and 1994 and explained the variable results of COX2 expression found in the literature. A tissue microarray was constructed of available tumour material, and ER, PgR, HER2, Ki67 and COX2 were examined by immunohistochemistry. Median follow-up was 19 years. Fifty-five percent (n = 369/677) of patients received no systemic treatment. COX2 was scored using a weighted histoscore. Analysis of COX2 expression in two groups based on the median (148; below vs. above) showed an increased hazard ratio (HR) of 1.35 (95% CI 1.05–1.75, P = 0.021) for disease-free survival (DFS) and of 1.39 (95% CI 1.03–1.82, P = 0.016) for overall survival (OS). However, COX2 did not remain independent in multivariate analysis. In patients with hormone receptor positive tumours, COX2 expression had a negative influence on outcome (low vs. high: DFS: HR 1.37, 95% CI 1.07–1.76, P = 0.013). This effect disappeared when endocrine therapy was administered (low vs. high: DFS: HR 0.93, 95% CI 0.51–1.70, P = 0.811) while it remained statistically significant when endocrine therapy was omitted (low vs. high: DFS: HR 1.48, 95% CI 1.12–1.94, P = 0.005). Our results show that COX2 plays a role in hormonal pathways. Our results can explain the results found in previously published studies.

Keywords

Early breast cancer COX2 Prognostic and predictive factors Endocrine therapy 

Notes

Acknowledgements

We thank Fiona Campbell, Alison Munro, Johanna Pedraza, InHwa Um and other colleagues of the Endocrine Cancer Group for their help in the laboratory. We thank Jan Molenaar for help with the database and Klaas van der Ham for pictures of immunohistochemistry-stained slides. This research has been supported by grants of the Dutch Surgical Foundation ‘Stichting Prof. Michaël-van Vloten Fonds’, by the Foundation ‘De Drie Lichten’ in the Netherlands and by an unrestricted educational research grant of Pfizer UK.

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMedGoogle Scholar
  2. 2.
    Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRefGoogle Scholar
  3. 3.
    Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144CrossRefPubMedGoogle Scholar
  4. 4.
    Harris RE, Chlebowski RT, Jackson RD et al (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res 63:6096–6101PubMedGoogle Scholar
  5. 5.
    Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84:1188–1192CrossRefPubMedGoogle Scholar
  6. 6.
    Rolland PH, Martin PM, Jacquemier J et al (1980) Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64:1061–1070PubMedGoogle Scholar
  7. 7.
    Boland GP, Butt IS, Prasad R et al (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90:423–429CrossRefPubMedGoogle Scholar
  8. 8.
    Costa C, Soares R, Reis-Filho JS et al (2002) Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55:429–434PubMedGoogle Scholar
  9. 9.
    Denkert C, Winzer KJ, Muller BM et al (2003) Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 97:2978–2987CrossRefPubMedGoogle Scholar
  10. 10.
    Haffty BG, Yang Q, Moran MS et al (2008) Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys 71:1006–1013CrossRefPubMedGoogle Scholar
  11. 11.
    Half E, Tang XM, Gwyn K et al (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62:1676–1681PubMedGoogle Scholar
  12. 12.
    Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90:455–460CrossRefPubMedGoogle Scholar
  13. 13.
    Kelly LM, Hill AD, Kennedy S et al (2003) Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol 29:707–710CrossRefPubMedGoogle Scholar
  14. 14.
    O’Connor JK, Avent J, Lee RJ et al (2004) Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys 58:1034–1040CrossRefPubMedGoogle Scholar
  15. 15.
    Park K, Han S, Shin E et al (2006) Cox-2 expression on tissue microarray of breast cancer. Eur J Surg Oncol 32:1093–1096CrossRefPubMedGoogle Scholar
  16. 16.
    Ristimaki A, Sivula A, Lundin J et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62:632–635PubMedGoogle Scholar
  17. 17.
    Schmitz KJ, Callies R, Wohlschlaeger J et al (2006) Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways. J Clin Pathol 59:685–691CrossRefPubMedGoogle Scholar
  18. 18.
    Singh-Ranger G, Jewell A, Thomas V, Mokbel K (2004) Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers. J Surg Oncol 88:100–103CrossRefGoogle Scholar
  19. 19.
    Soslow RA, Dannenberg AJ, Rush D et al (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637–2645CrossRefPubMedGoogle Scholar
  20. 20.
    Spizzo G, Gastl G, Wolf D et al (2003) Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 88:574–578CrossRefPubMedGoogle Scholar
  21. 21.
    Witton CJ, Hawe SJ, Cooke TG, Bartlett JM (2004) Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 45:47–54CrossRefPubMedGoogle Scholar
  22. 22.
    Zerkowski MP, Camp RL, Burtness BA et al (2007) Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Invest 25:19–26CrossRefPubMedGoogle Scholar
  23. 23.
    Dubois RN, Abramson SB, Crofford L et al (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063–1073PubMedGoogle Scholar
  24. 24.
    McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067–9072CrossRefPubMedGoogle Scholar
  25. 25.
    Leyland-Jones BR, Ambrosone CB, Bartlett J et al (2008) Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol 26:5638–5644CrossRefPubMedGoogle Scholar
  26. 26.
    Bartlett J, Mallon E, Cooke T (2003) The clinical evaluation of HER-2 status: which test to use? J Pathol 199:411–417CrossRefPubMedGoogle Scholar
  27. 27.
    Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80:1943–1949CrossRefPubMedGoogle Scholar
  28. 28.
    Henriksen KL, Rasmussen BB, Lykkesfeldt AE et al (2007) Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 60:397–404CrossRefPubMedGoogle Scholar
  29. 29.
    Kirkegaard T, Edwards J, Tovey S et al (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48:787–794CrossRefPubMedGoogle Scholar
  30. 30.
    Kirkegaard T, Witton CJ, McGlynn LM et al (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207:139–146CrossRefPubMedGoogle Scholar
  31. 31.
    Faratian D, Kay C, Robson T et al (2009) Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience. Histopathology 55(5):587–593CrossRefPubMedGoogle Scholar
  32. 32.
    Turbin DA, Leung S, Cheang MC et al (2008) Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat 110:417–426CrossRefPubMedGoogle Scholar
  33. 33.
    Altman DG, Machin D, Bryant TN, Gardner MJ (2000) Statistics with confidence. British Medical Journal Books, BristolGoogle Scholar
  34. 34.
    Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Johanna G. H. van Nes
    • 1
  • Esther M. de Kruijf
    • 1
  • Dana Faratian
    • 2
  • Cornelis J. H. van de Velde
    • 1
  • Hein Putter
    • 3
  • Claire Falconer
    • 2
  • Vincent T. H. B. M. Smit
    • 4
  • Charlene Kay
    • 2
  • Marc J. van de Vijver
    • 5
  • Peter J. K. Kuppen
    • 1
  • John M. S. Bartlett
    • 2
  1. 1.Department of SurgeryLeiden University Medical CentreLeidenThe Netherlands
  2. 2.Endocrine Cancer Group, Department of PathologyCancer Research Center, Western General HospitalEdinburghUK
  3. 3.Department of Medical StatisticsLeiden University Medical CentreLeidenThe Netherlands
  4. 4.Department of PathologyLeiden University Medical CentreLeidenThe Netherlands
  5. 5.Department of PathologyAmsterdam Medical CentreAmsterdamThe Netherlands

Personalised recommendations